Trial Profile
efficacy of sobaiovir and daclatasvir in the treatment of hepatitis C in patients with thalassemia major
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 23 Dec 2022
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Nov 2022 Results published in the Archives of Medical Research
- 21 Dec 2017 New trial record